Errant Gene Therapeutics (“EGT”) asks European Authorities to Re-examine the Approval Process of Zynteglo, While US Litigation Moves Forward

Errant Gene Therapeutics (“EGT”) asks European Authorities to Re-examine the Approval Process of Zynteglo, While US Litigation Moves Forward

Picking up on the ongoing “Family Man” saga, in New York Court, EGT claims that Zynteglo, the Bluebird Bio product for Thalassemia, created Clonal Dominance. EGT alleges that Bluebird Bio assisted Memorial Sloan Kettering in orchestrating the sabotage of EGT’s product Thalagen, allowing Bluebird to fix what EGT believes was a faulty vector in a bid to gain proprietary data and eliminate EGT. EGT alleged that there was no other direct competition. In this assertion, with EGT out of the way, Bluebird subsequently raised the price of Zynteglo from $750,000 (price stated on page 43 of the 2013 JP Morgan report on Bluebird) to $1,800,000. Notably, Article 30 of the European Economic Community (EEC) Treaty states that anti-competitive behavior and violation of IP is a reason to restrict commercialization of a product in the European Member States. Does all of this apply in this particular context? Only a court could determine. The case shines a light on just how rough and tough biotech competition can become. 

TrialSite opted to learn about and report on the “Family Man” saga due to concerns involving  uncompetitive actions leading to the destruction of companies....

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee